KR102832951B1 - 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 - Google Patents
1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 Download PDFInfo
- Publication number
- KR102832951B1 KR102832951B1 KR1020227040086A KR20227040086A KR102832951B1 KR 102832951 B1 KR102832951 B1 KR 102832951B1 KR 1020227040086 A KR1020227040086 A KR 1020227040086A KR 20227040086 A KR20227040086 A KR 20227040086A KR 102832951 B1 KR102832951 B1 KR 102832951B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- compound represented
- formula
- linear
- branched alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010330893 | 2020-04-26 | ||
| CN202010330893.1 | 2020-04-26 | ||
| CN202110288141 | 2021-03-17 | ||
| CN202110288141.8 | 2021-03-17 | ||
| PCT/CN2021/089660 WO2021218863A1 (zh) | 2020-04-26 | 2021-04-25 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230004662A KR20230004662A (ko) | 2023-01-06 |
| KR102832951B1 true KR102832951B1 (ko) | 2025-07-10 |
Family
ID=78374068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227040086A Active KR102832951B1 (ko) | 2020-04-26 | 2021-04-25 | 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12559471B2 (https=) |
| EP (1) | EP4144725B1 (https=) |
| JP (1) | JP7693709B2 (https=) |
| KR (1) | KR102832951B1 (https=) |
| CN (1) | CN115667236B (https=) |
| AU (1) | AU2021262281B2 (https=) |
| BR (1) | BR112022021228A2 (https=) |
| CA (1) | CA3172692C (https=) |
| WO (1) | WO2021218863A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115605202B (zh) | 2020-03-26 | 2025-10-28 | 盐野义制药株式会社 | 具有血清素受体结合活性的芳香族杂环衍生物 |
| CN121039114A (zh) | 2023-04-21 | 2025-11-28 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用 |
| WO2025044768A1 (zh) * | 2023-08-29 | 2025-03-06 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的制备方法和其中间体及其制备方法 |
| CN120329280A (zh) * | 2024-01-17 | 2025-07-18 | 江苏恩华药业股份有限公司 | 取代的1,2,4-四氢-3h-苯并二氮䓬-3-酮衍生物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007011820A2 (en) | 2005-07-15 | 2007-01-25 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| CN103702983A (zh) | 2011-05-12 | 2014-04-02 | 艾伯维德国有限责任两合公司 | 苯并氮杂环庚烯衍生物、含有它们的药物组合物及其在治疗中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60161986A (ja) * | 1983-12-24 | 1985-08-23 | Nippon Soda Co Ltd | イミダゾ（１，５−ａ）ピリジン−３−オン誘導体及びその製造方法 |
| ES2197160T3 (es) * | 1992-12-21 | 2004-01-01 | Smithkline Beecham Corp | Antagonistas fibronogeno bicicliclos. |
| EP0960104B1 (en) * | 1996-04-17 | 2004-06-16 | Bristol-Myers Squibb Pharma Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| GT199800109A (es) * | 1997-08-06 | 2000-01-13 | Derivados de n-sulfonilglicinalquiniloxifenetilamida microbicidas. | |
| JP2003503476A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミド誘導体 |
| SI1720836T1 (sl) * | 2004-02-25 | 2014-06-30 | Eli Lilly And Company | 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja |
| US7473778B2 (en) * | 2005-12-24 | 2009-01-06 | Boehringer Ingelheim International Gmbh | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one |
| US20100222326A1 (en) | 2007-04-27 | 2010-09-02 | Ucb Pharma, S.A. | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders |
| JP5502733B2 (ja) * | 2007-07-26 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ２ａ及びｄ３受容体の二重のモジュレーター |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
-
2021
- 2021-04-25 JP JP2022563189A patent/JP7693709B2/ja active Active
- 2021-04-25 CA CA3172692A patent/CA3172692C/en active Active
- 2021-04-25 BR BR112022021228A patent/BR112022021228A2/pt unknown
- 2021-04-25 KR KR1020227040086A patent/KR102832951B1/ko active Active
- 2021-04-25 EP EP21796540.9A patent/EP4144725B1/en active Active
- 2021-04-25 WO PCT/CN2021/089660 patent/WO2021218863A1/zh not_active Ceased
- 2021-04-25 CN CN202180029971.7A patent/CN115667236B/zh active Active
- 2021-04-25 AU AU2021262281A patent/AU2021262281B2/en active Active
-
2022
- 2022-10-20 US US18/048,340 patent/US12559471B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007011820A2 (en) | 2005-07-15 | 2007-01-25 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| CN103702983A (zh) | 2011-05-12 | 2014-04-02 | 艾伯维德国有限责任两合公司 | 苯并氮杂环庚烯衍生物、含有它们的药物组合物及其在治疗中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7693709B2 (ja) | 2025-06-17 |
| BR112022021228A2 (pt) | 2022-12-06 |
| JP2023522078A (ja) | 2023-05-26 |
| EP4144725B1 (en) | 2025-11-26 |
| AU2021262281A1 (en) | 2022-11-24 |
| US12559471B2 (en) | 2026-02-24 |
| EP4144725A1 (en) | 2023-03-08 |
| WO2021218863A1 (zh) | 2021-11-04 |
| CN115667236A (zh) | 2023-01-31 |
| CA3172692C (en) | 2024-05-14 |
| AU2021262281B2 (en) | 2024-11-28 |
| US20230132621A1 (en) | 2023-05-04 |
| CA3172692A1 (en) | 2021-11-04 |
| CN115667236B (zh) | 2024-04-26 |
| EP4144725C0 (en) | 2025-11-26 |
| KR20230004662A (ko) | 2023-01-06 |
| EP4144725A4 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102832951B1 (ko) | 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 | |
| JP7044375B2 (ja) | Ｐｔｐｎ１１の複素環式阻害剤 | |
| DE60127002T2 (de) | Pharmazeutische zusammensetzung | |
| JP2021523221A (ja) | Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター | |
| US10428051B2 (en) | Substituted amide derivatives having multimodal activity against pain | |
| CN102666489B (zh) | 鞘氨醇激酶抑制剂 | |
| CN102316732A (zh) | 氮杂䓬并[4,5-b]吲哚以及使用方法 | |
| JP2023522078A5 (https=) | ||
| JP6898310B2 (ja) | ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法 | |
| JP5017094B2 (ja) | 置換ジアザ−スピロ−［５．５］−ウンデカン誘導体およびそれらのニューロキニン拮抗薬としての使用 | |
| KR20150082616A (ko) | 디히드로피라졸 gpr40 조절제 | |
| CN105294654A (zh) | Alk激酶抑制剂及其制备方法和应用 | |
| CN116444484B (zh) | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的盐及应用 | |
| WO2019158070A1 (zh) | A2a和/或a2b受体拮抗剂 | |
| TWI868068B (zh) | 氮雜苯並咪唑化合物及醫藥 | |
| JP2020504139A (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| KR20220101142A (ko) | 기능성 소화관 장애 및 구강 건조증의 치료제 및 예방제 | |
| KR20070007347A (ko) | 치환된 4-알킬- 및 4-알카노일-피페리딘 유도체 및뉴로키닌 길항제로서의 그 용도 | |
| EP3333165A1 (en) | Piperazine derivative | |
| EA012421B1 (ru) | Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина | |
| JP2021042231A (ja) | 中枢神経系に関連している疾患または病態の治療に有用であるｎ−（ヘテロ）アリール置換複素環誘導体 | |
| JP2009504755A (ja) | 治療剤としての縮合三環式ｍＧｌｕＲ１アンタゴニスト | |
| CN111440148B (zh) | 一种腺苷受体拮抗剂的制备方法 | |
| HK40080583B (zh) | 1，5-二氢-2，4-苯二氮䓬-3-酮衍生物及其应用 | |
| HK40080583A (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |